Characteristics of Heart Rate Tracings in Preterm Fetus by Hurtado Sánchez, María F. et al.
medicina
Review
Characteristics of Heart Rate Tracings in Preterm Fetus
Maria F. Hurtado-Sánchez 1, David Pérez-Melero 2, Andrea Pinto-Ibáñez 3 , Ernesto González-Mesa 4 ,




Pérez-Melero, D.; Pinto-Ibáñez, A.;
González-Mesa, E.; Mozas-Moreno, J.;
Puertas-Prieto, A. Characteristics of
Heart Rate Tracings in Preterm Fetus.
Medicina 2021, 57, 528. https://
doi.org/10.3390/medicina57060528
Academic Editor: Simone Ferrero
Received: 14 May 2021
Accepted: 23 May 2021
Published: 25 May 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Obstetrics and Gynecology Service, Virgen de las Nieves University Hospital, 18014 Granada, Spain;
franihurs@gmail.com (M.F.H.-S.); apuertas51@hotmail.com (A.P.-P.)
2 Anesthesiology, Resuscitation and Pain Therapy Service, Virgen de las Nieves University Hospital,
18014 Granada, Spain; dpmelero@yahoo.es
3 Obstetrics and Gynecology Service, Poniente Hospital, 04700 El Ejido (Almería), Spain; apintoib@gmail.com
4 Obstetrics and Gynecology Service, Regional University Hospital of Malaga, 29011 Malaga, Spain;
egonzalezmesa@gmail.com
5 Department of Obstetrics and Gynecology, University of Granada, 18016 Granada, Spain
6 Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud
Pública-CIBERESP), 28029 Madrid, Spain
7 Biohealth Research Institute (Instituto de Investigación Biosanitaria Ibs.GRANADA), 18014 Granada, Spain
* Correspondence: jmozas@ugr.es; Tel.: +34-958242867
Abstract: Background and Objectives: Prematurity is currently a serious public health issue worldwide,
because of its high associated morbidity and mortality. Optimizing the management of these preg-
nancies is of high priority to improve perinatal outcomes. One tool frequently used to determine
the degree of fetal wellbeing is cardiotocography (CTG). A review of the available literature on
fetal heart rate (FHR) monitoring in preterm fetuses shows that studies are scarce, and the evidence
thus far is unclear. The lack of reference standards for CTG patterns in preterm fetuses can lead
to misinterpretation of the changes observed in electronic fetal monitoring (EFM). The aims of this
narrative review were to summarize the most relevant concepts in the field of CTG interpretation in
preterm fetuses, and to provide a practical approach that can be useful in clinical practice. Materials
and Methods: A MEDLINE search was carried out, and the published articles thus identified were
reviewed. Results: Compared to term fetuses, preterm fetuses have a slightly higher baseline FHR.
Heart rate is faster in more immature fetuses, and variability is lower and increases in more mature
fetuses. Transitory, low-amplitude decelerations are more frequent during the second trimester.
Transitory increases in FHR are less frequent and become more frequent and increase in amplitude as
gestational age increases. Conclusions: The main characteristics of FHR tracings changes as gestation
proceeds, and it is of fundamental importance to be aware of these changes in order to correctly
interpret CTG patterns in preterm fetuses.
Keywords: fetal heart rate; preterm fetus; cardiotocography; fetal heart rate patterns; electronic
fetal monitoring
1. Introduction
Cardiotocography (CTG) aims to identify fetal heart rate (FHR) patterns that may
indicate a risk, so that clinicians can forestall problems with measures intended to improve
perinatal outcomes. As a tool with high sensitivity but very low specificity, the false positive
rate of CTG findings approaches 60%. This means that watchful waiting is advised when
a CTG tracing is considered normal, whereas abnormal FHR tracings offer no certainties
regarding the hypoxic status of the fetus or possible acidosis [1].
In an effort to determine the influence of CTG on perinatal outcomes, Alfiveric et al.
updated a Cochrane review in 2017 [2] in order to evaluate the effectiveness and safety of
continuous CTG as a form of electronic fetal monitoring (EFM) for fetal assessment during
labor, compared to intermittent monitoring. The authors concluded that CTG during
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labor is associated with reduced rates of neonatal seizures, but no clear differences in
cerebral palsy, infant mortality or other standard measures of neonatal wellbeing. However,
continuous CTG was associated with an increase in cesarean deliveries and instrumental
vaginal births.
In the particular case of preterm gestations, no clinical practice guidelines are currently
available for EFM, and published studies on CTG in preterm fetuses are scarce. Many
characteristics of CTG tracings depend on gestational age and reflect the degree of develop-
ment and maturity of regulatory centers in the central nervous system and cardiovascular
system. This makes it imperative to understand these physiological characteristics in order
to correctly interpret FHR patterns in preterm fetuses [3].
Because they are less developed and less mature, preterm fetuses may respond to
stress in anomalous ways, giving rise to situations of permanent hypoxia in the fetal brain
at threshold values that may be lower than in term fetuses [4]. As a result, the classic
characteristics of CTG tracings in healthy term fetuses exposed to hypoxic situations may
not be observable in preterm fetuses.
The FHR is regulated by the autonomous nervous system, and during fetal develop-
ment the sympathetic nervous system develops much earlier than the parasympathetic
system, which develops mainly throughout the third trimester. The sympathetic nervous
system is activated in situations of stress; accordingly, preterm fetuses will have a higher
baseline FHR with an apparent reduction in variability, owing to the predominant action of
the sympathetic nervous system and lesser opposition from the parasympathetic system [3].
The evidence suggests that non-reassuring CTG tracings are of greater importance
for adverse neonatal outcomes in preterm fetuses than in term fetuses. In this regard,
Freeman et al. [5] claimed that 20% of term fetuses have signs of neurological depression at
birth associated with non-reassuring CTG patterns, compared to 70–80% of preterm fetuses
with the same type of FHR tracings. These authors sustained that preterm fetuses are more
susceptible to hypoxic damage and have a greater tendency to develop prematurity-related
complications if they are born with hypoxia or acidosis. In addition, they claimed that the
change from reassuring to non-reassuring CTG features occurs more frequently and faster
in preterm fetuses than term fetuses.
Another study by Matsuda et al. [6] analyzed the critical period of non-reassuring
FHR patterns in preterm gestation. Of a total of 772 preterm deliveries, they observed
non-reassuring FHR patterns in 181 (23.4%), consisting of recurrent late decelerations with
loss of variability, prolonged decelerations, severe recurrent variable decelerations, and
recurrent late decelerations. Umbilical cord artery blood pH in cases of recurrent late
decelerations with loss of variability (7.15 ± 0.11, p < 0.01) and prolonged decelerations
(7.17 ± 0.16, p < 0.01) was significantly lower than in the group with reassuring FHR
patterns (7.29 ± 0.06). Fetal acidosis was more frequent in fetuses with recurrent late
decelerations with loss of variability (24.1%) and prolonged decelerations (22.9%) than
in those with other non-reassuring FHR patterns or with reassuring FHR patterns (2.9%).
The largest differences compared to term fetuses were that preterm fetuses sometimes
developed abnormal FHR patterns rapidly, and these patterns sometimes became more
serious much more rapidly than in term fetuses.
The aims of this narrative review were to summarize the most relevant concepts in
the field of interpretation of CTG tracings in preterm fetuses, and to provide a practical
approach that can be useful in clinical practice.
2. Materials and Methods
A MEDLINE search was carried out covering the period from 1980 until 2020. Searches
with the terms “cardiotocography AND preterm fetus” identified 98 published studies.
After studies of fetuses with intrauterine growth restriction (IGR) were removed, 65 pub-
lications remained. A further 57 studies were excluded as being outside the scope and
aims of the present review, i.e., to analyze the main characteristics of CTG in preterm fe-
tuses. Searches with the terms “electronic FHR monitoring AND preterm fetus” identified
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142 publications; after excluding those that centered on fetuses with IGR, 104 studies re-
mained, and after excluding those that did not comply with our review criteria, 22 remained.
A third search with the terms “FHR patterns AND preterm fetus” located 111 published
items, of which 90 remained in our sample after those focusing on fetuses with IGR were
excluded. After excluding those that did not comply with our review criteria, 20 remained.
The pooled results of the three searches yielded a total of 50 publications, of which a further
16 were excluded as duplicates. The final sample consisted of 34 studies, 7 of which had
been published within the previous 10 years (Figure 1).
Figure 1. Flow diagram of identification of eligible studies. FHR: fetal heart rate.
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3. Results and Discussion
3.1. Baseline FHR
Classic studies show that FHR increases steadily until week 16 of gestation and
decreases thereafter by one beat per minute (bpm) each week, as a result of maturation
of the parasympathetic nervous system [7]. Preterm fetuses, with their less developed
parasympathetic system, usually have a higher baseline FHR compared to term or post-
term fetuses, with their more developed parasympathetic system.
There is broad consensus among most scientific societies (e.g., International Feder-
ation of Gynecology and Obstetrics (IFGO) and American College of Obstetricians and
Gynecologists (ACOG)) and clinical practice guidelines (e.g., The National Institute for
Health and Care Excellence (NICE) and The Society of Obstetricians and Gynaecologists
of Canada (SOGC)) in considering the normal range of FHR to be 110–160 bpm, although
occasionally a term fetus may have a baseline FHR between 90 and 110 bpm as a con-
sequence of greater parasympathetic nervous system maturity. This can be considered
normal if other parameters in the CTG tracing are reassuring. Nonetheless, some current
thinking advocates a less stringent application of the criteria for normal findings generally
used to interpret CTG tracings, given that some parameters used to evaluate them may be
generalized without due consideration for the particular characteristics of each fetus, e.g.,
gestational age [8].
As gestational age progresses, maturation of the parasympathetic nervous system
leads to a decrease in baseline FHR, although it generally remains within the normal range
of 110 to 160 bpm. In preterm fetuses, baseline FHR is close to the generally accepted upper
limit of normality, and as noted, decreases as gestation proceeds [9]. Shuffrey et al. [10]
published the largest longitudinal study carried out to date to analyze changes in FHR,
variability, and fetal body movements throughout gestation in healthy fetuses. This study
monitored 1655 fetuses during Weeks 20–24 (GA1), Weeks 28–32 (GA2), and Weeks 34–38
(GA3). The authors found that FHR decreased as gestation progressed, with mean rates
of 144.1 ± 4.8 bpm in GA1, 139.5 ± 5.7 bpm in GA2, and 136.4 ± 6.7 bpm in GA3. These
results were consistent with earlier studies [11–16] such as the one published by Amorim-
Costa et al. [11], who followed 145 cases and also reported decreasing FHR as gestation
progressed, with a mean rate of 143.7 bpm at 24 weeks, 138.9–138.4 bpm at 28–32 weeks,
and 135.5–135.4 bpm at 34–38 weeks.
The findings published in these studies are consistent with unpublished data for a
population analyzed at Hospital Universitario Virgen de las Nieves (HUVN) in Granada
(Spain) for a descriptive, observational study of CTG tracings in preterm fetuses with no
gestational disorders or anomalies in the absence of uterine contractions (Table 1). The
CTG tracings were studied for a total of 118 preterm fetuses between Weeks 22 and 36
of gestation. In 66 cases (55.9%) the fetus was younger than 30 weeks of gestation, and
in remaining 52 cases (44.1%) comprised preterm fetuses of more 30 weeks of gestation.
Mean baseline FHR was 141 ± 8 bpm. Only one fetus (0.8%) had a baseline FHR lower
than 110 bpm; all other fetuses (99.2%) had an FHR within the commonly accepted normal
range, i.e., between 110 and 160 bpm. Mean baseline FHR in the group of fetuses of less
than 30 weeks of gestation was 144 ± 6 bpm, versus 138 ± 8 bpm (p < 0.05) in fetuses of
30 weeks’ gestation or more; in other words, the findings were consistent with currently
available evidence.
In preterm fetuses, as in term fetuses, an FHR higher than 160 bpm is considered
tachycardia. However, this event is more frequent in preterm fetuses and is more predictive
of acidemia, low Apgar scores, and adverse neonatal outcomes compared to tachycardia
observed in term fetuses [4].
The effects on FHR of certain drugs used in preterm gestations merit particular
attention. In preterm fetuses, ritodrine causes fetal tachycardia as a result of β-adrenergic
receptor stimulation, associated with decreased variability. In addition, corticosteroids are
also related with increases in FHR [17].
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Table 1. Cardiotocographic tracings in 118 preterm fetuses at Virgen de las Nieves University
Hospital, Granada, Spain.
<30 Weeks ≥30 Weeks Total p
n 66 (55.9%) 52 (44.1%) 118 (100%)
Baseline FHR (bpm) 144 ± 6 138 ± 8 141 ± 8 <0.05
Minimal variability (≤5 bpm) n (%) 11 (57.9%) 8 (42.1%) 19 (16.1%) ns
Moderate variability (6–25 bpm) n (%) 54 (55.7%) 43 (44.3%) 97 (82.2%) ns
Reactivity * 30 (47.6%) 33 (52.4%) 63 (53.4%) ns
Decelerations 14 (85.7%) 3 (14.3%) 17 (14.4%) <0.05
* Presence of ≥2 transitory increases in FHR (fetal heart rate) at least 10 bpm in amplitude and at least 10 s in
duration within a 20-min period. n (%): number (percentage); ns: not significant.
3.2. Transitory FHR Accelerations (Reactivity)
Transitory FHR accelerations (reactivity) occur as a result of somatic activity by fetus,
and are first apparent in the second trimester of gestation. As the fetus matures, the number
of transitory FHR accelerations increases as the time elapsed between episodes decreases.
Controversy continues to surround the percentage of fetuses with reactivity at different
gestational ages. Some research [18] found that at 24 weeks of gestation only 50% of healthy
fetuses showed transitory FHR accelerations, and that at 30 weeks of gestation these
accelerations were seen in more than 95%. In contrast, other studies [16,19,20] claimed
that between Weeks 20 and 30 only 13% of fetuses showed no transitory FHR increases
over a period of 60 min, and that between Weeks 24 and 32, fetal respiratory movements
and the number of fetal gross body movements increased. These studies concluded that
20% of transitory FHR accelerations were unrelated to fetal movements, and that 30% of
fetal movements were not associated with transitory FHR increases in fetuses of less than
32 weeks’ gestation.
Data from the HUVN in Granada (Table 1) show that 75.4% of preterm fetuses between
32 and 36 weeks of gestation had transitory FHR increases, and 53.4% of the CTG tracings
showed reactivity, i.e., at least two transitory increases greater than 10 bpm and longer than
10 s over a 20-min period. Of these increases, 47.6% were seen in CTG tracings for fetuses
of <30 weeks’ gestation and 52.4% were seen in fetuses of ≥30 weeks, with no statistically
significant difference between gestational age groups.
The National Institute of Child Health and Human Development [21] and later the
ACOG [22] defined transitory FHR increases in gestations of less than 32 weeks as increases
of ≥10 bpm above baseline during ≥10 s. The distinction between gestations of less than
32 weeks vs. the classic definition of ≥15 bpm during ≥15 s in gestations of ≥32 weeks
was justified on the basis of changes seen in FHR as the autonomous nervous system
matures. Despite widespread acceptance that the amplitude of transitory increases is lower
in preterm fetuses than in term fetuses, to date there have been no well-designed trials that
support this assumption or that establish the safety of this claim [23].
In light of these findings, it is generally accepted that before 32 weeks of gestation
the frequency and amplitude of FHR accelerations are lower. Accordingly, before this
gestational age the CTG tracing can be considered indicative of reactivity if it shows two
FHR accelerations of at least 10 bpm above the baseline value, and if the accelerations last
at least 10 s (10 × 10 criterion).
The validity of the 10 × 10 criterion before 32 weeks of gestation has been analyzed in
two studies. In a sample of 143 pregnancies [23], groups matched for other characteristics
were compared according to the 10 × 10 reactivity criterion (n = 72) vs. the 15 × 15 criterion
(n = 73). The frequency of adverse perinatal outcomes was similar when CTG reactivity
was defined with the 10 × 10 criterion rather than the conventional 15 × 15 criterion.
However, the statistical significance was insufficient to confirm the safety of using the
10 × 10 criterion before 32 weeks of gestation. Another study of 488 pregnancies [24]
used EFM to compare the relationship of the 10 × 10 vs. 15 × 15 evaluation criteria for
FHR accelerations with perinatal outcomes. This analysis of 7100 CTG tracings found no
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association between either reactivity criterion and perinatal outcomes in terms of perinatal
mortality, need for neonatal resuscitation, 5-mintute Apgar score less than 7, mechanical
ventilation, or intraventricular hemorrhage. Current evidence is thus insufficient to dispel
questions regarding the value of 10 × 10 transitory FHR accelerations in preterm fetuses
that were previously found to be mature enough to generate 15-bpm accelerations during
15 s (15 × 15).
Reactivity in preterm fetuses can be affected by a number of drugs. The findings
with regard to magnesium sulfate are inconclusive, although most studies have reported
a decrease in the frequency of transitory FHR accelerations [25]. A study of the effect of
corticosteroids [17] found these drugs were able to increase fetal movements and FHR
accelerations within the first 24 h after administration, followed by a reduction in both
during the subsequent 96 h, although these changes did not imply fetal deterioration.
3.3. Decelerations in FHR
In fetuses between 20 and 30 weeks of gestation the CTG tracing usually discloses
FHR decelerations in the absence of uterine contractions. These brief, low-amplitude decel-
erations frequently appear in intrapartum CTG tracings, as reported by Sorokin et al. [7].
Variable decelerations are more frequent in preterm fetuses both antepartum and
intrapartum; in the latter period these decelerations appear in 70–75% of all preterm fetuses
compared to 30–50% of term fetuses. These changes are believed to be related with the
smaller amount of Wharton’s jelly in the umbilical cord and greater contractile force of the
heart owing to the lesser degree of development of the fetal myocardium. Variable intra-
partum decelerations are associated with a higher rate of hypoxemia, acidemia, abnormal
neurological processes, and adverse neonatal outcomes in the long term. Current evidence
suggests a relationship with intraventricular hemorrhaging via a mechanism independent
of fetal acidemia [3].
The same trend in variable decelerations was seen in the antepartum CTG data for
preterm fetuses analyzed at HUVN in Granada (Table 1). At least one typical variable
deceleration was seen in 5.6% of the cases, and these alterations were seen periodically
in 3.2% of the cases. The differences between gestational age groups were significant:
decelerations were seen in 85.7% of fetuses at <30 weeks compared to 14.3% of fetuses at
≥30 weeks (p < 0.05).
The frequency of late decelerations was similar in preterm and term fetuses, although
obstetric conditions associated with this type of deceleration were more frequent in the
former group (uteroplacental insufficiency, intra-amniotic infection, preeclampsia, IGR,
and abruptio placentae). Late decelerations are of more concern in preterm fetuses because
of their association with hypoxemia, acidemia and abnormal neurological processes in the
long term. In this connection, Matsuda et al. [6] found that the FHR features associated most
frequently with low cord arterial blood pH at birth were late decelerations accompanied by
decreased variability, and prolonged decelerations.
3.4. FHR Variability
Low or absent variability (<5 bpm) is more frequent in preterm fetuses. Research
by Shuffrey et al. [10] confirmed that mean FHR variability increases during gestation
from 2.9 ± 0.7 bpm at 24–26 weeks to 3.7 ± 0.9 bpm at 28–32 weeks, and 4.3 ± 0.1 bpm
at 34–36 weeks. Among the preterm fetuses analyzed at our center (Table 1), 16.1% had
minimal variability, and 82.2% had moderate variability (between 6 and 25 bpm). In the
group of fetuses with a gestational age < 30 weeks, 57.9% showed diminished variability
compared to 42.1% of fetuses in the group of ≥30 weeks’ gestation, whereas moderate
variability was seen in 55.7% and 44.3% of the fetuses, respectively, in these two groups,
although the differences between groups were not statistically significant.
An indicator of fetal wellbeing is the presence of cyclic FHR patterns, with periods
of activity characterized by increased variability alternating with periods of apparently
decreased variability. As gestational age increases, FHR patterns tend to stabilize [18].
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Consequently, in very premature fetuses these cyclic features may not be present, owing to
functional immaturity of the central nervous system rather than to the effect of hypoxia.
Signs of FHR variability in CTG tracings are also affected by certain drugs. For exam-
ple, biophysical activities in fetuses are depressed after the administration of betamethasone
to favor pulmonary maturation. In this connection, Mulder et al. [26] found a significant
decrease in FHR variability after the administration of this drug, and their findings are
consistent with observations from a randomized study by Senat et al. [27], who found that
after betamethasone treatment was suspended, FHR variability returned to pretreatment
values within one week. These authors found no differences in FHR after the administra-
tion of dexamethasone for fetal pulmonary maturation. However, Rotmensch et al. [28]
reported decreased FHR variability after treatment with both drugs, and noted the effect
was more pronounced with betamethasone than with dexamethasone. Regarding other
drugs, magnesium sulfate has been associated with a lower FHR, decreased variability,
and fewer prolonged decelerations, albeit with no evidence of adverse effects on neonatal
outcomes [29].
A systematic summary of the findings regarding the relationship between FHR signal
features and the degree of prematurity is presented in Table 2.
Table 2. Systematic summary of the findings regarding the relationship between FHR signal features and the degree
of prematurity.
<26 Weeks 26–32 Weeks >32 Weeks
Baseline FHR (mean bpm) 144 139 136
Reactivity (transitory
FHR accelerations)
May not be present or
very reduced Progressively increases Similar to term fetuses





Variability Reduced Reaches normal >30 weeks Similar to term fetuses
4. Conclusions
Despite the absence of standards for determining which characteristics of CTG tracings
or FHR patterns can be considered unequivocally normal for preterm fetuses, what little
evidence has accumulated to date shows clear differences in FHR patterns between preterm
and term fetuses, and these differences must be taken into account to ensure that the
patterns are evaluated appropriately. In summary, the four main features of FHR patterns
in preterm fetuses compared to term fetuses are: (1) slightly higher baseline FHR, with
increasing immaturity associated with increasing FHR (although the normal range remains
110 to 160 bpm), (2) lower variability, which increases as the fetus matures, (3) more
frequent appearance of transitory, low-amplitude decelerations in the second trimester
of gestation, and (4) lower frequency of transitory FHR increases, which become more
frequent and increase in amplitude as gestational age increases.
All this information from CGT tracings in preterm fetuses must be transferred to
clinical decision making. In this sense, it can be stated that (1) FHR of the preterm fetuses
must be assessed according to its gestational age, (2) the assessment should be made
taking into account whether the pregnancy is accompanied by pathology and the possible
influence of the drugs administered to the pregnant woman, (3) fetal damage after hypoxic
situations is earlier in the preterm than at term fetuses, so clinical decisions must take this
variable into account, and (4) before accepting that deviations from normality of the FHR
are due only to prematurity, it must be taken into account that their origin may be in a
concomitant fetal pathological situation.
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